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Dear Editor,
An 83-year-old man was referred to our skin cancer 
unit because staging whole computed tomography (CT) 
scans (Fig. 1A) revealed multiple lung and mediastinal 
lymph node metastases of cutaneous apocrine carci-
noma (Fig. 2A), which had been treated by a wide sur-
gical excision and lymph node dissection (with 
metastases in 13 of 17 removed lymph nodes) 3 months 
before. The patient was staged as metastatic apocrine 
carcinoma and was discussed in our multidisciplinary 
tumour board. After considering several factors 
including the lack of significant comorbidities, excellent 
Eastern Cooperative Oncology Group status, lack of
effective established treatments and promising effect of
programmed cell death protein 1 (PD-1) inhibitors on
several forms of solid cancers, a decision to initiate a
treatment with pembrolizumab was made. He received a
dose of 2 mg/kg body weight intravenously every 3
weeks. Treatment was well tolerated without adverse
effects. CT scans after the first 4 cycles (at week 12)
indicated stable disease according to the iRECIST
criteria with a sum of measures (SOM) of 54 for 3 target
lesions compared to the baseline SOM of 56 [1]. Treat-
ment was continued and re-staging after further 4 cycles
(week 24) revealed partial remission. After, overall, 16
cycles (48 weeks from baseline), the patient showed
ongoing partial response with a SOM of 35 (>30%
decrease). The enlarged mediastinal and hilar lymph
nodes decreased to normal size (Fig. 1B), and the lung
metastases remained stable. Currently, the patient is
continuing the treatment.
Immunohistochemistry for PD-L1 (clone 28-8;
Abcam), PD-1 (clone NAT 105; Cell Marque AK) and
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer.com
European Journal of Cancer 90 (2018) 146e148
2epidermal growth factor receptor (EGF-R) (clone 3C6;
Roche) was analysed in the primary tumour on serial
sections using a Roche-Ventana Benchmark Ultra
automated stainer. The evaluation of immunohisto-
chemistry was performed semiquantitatively. Normal
tonsil was used as on-slide positive control. A predom-
inantly cytoplasmic immunoreactivity in about 60% of
the tumour cells for PD-L1 (Fig. 2B) and a moderately
intense immunoreactivity in about 70% of the tumour
cells for EGF-R were found, whereas the tumour was
negative for PD-1.
1. Comment
Cutaneous apocrine adenocarcinoma is a rare form of
sweat gland cancer with main sites of predilection on the
trunk and the head/neck region. The established therapy
for a localised tumour is wide local excision with a
1e2 cm clear margin. The most important predictor of
survival is the lymph node status with positive lymph
nodes associated with a poor prognosis. For metastatic
disease, no effective treatment is currently established.
The 5-year overall survival is less than 10% [2,3].
Clinical trials cannot practically be conducted for
apocrine gland carcinoma because of the rarity of this
malignancy. Accordingly, there are no guidelines for the
treatment of metastatic disease. Evidence of successful
chemotherapeutic regimens or more recently human
epidermal growth factor receptor 2 is limited in the
literature to isolated case report or specific cancers [3,4].
Inhibition of the PD-1 achieves a high effective anti-
tumour activity in several forms of cutaneous cancers
including not only melanoma and Merkel cell carcinoma
but also cutaneous squamous cell carcinoma [5,6].
Fig. 1. Enlarged hilar lymph node at baseline CT (A) with
decrement to normal size after 16 cycles of pembrolizumab (B)
(marking D7 with diameter in centimetres). CT, computed
tomography.
Fig. 2. The tumour cells are arranged in glandular formations and
characterised by eosinophilic cytoplasm and large nuclei with
prominent nucleoli Hematoxylin and Eosin (HE) (A). Strong
membranous and cytoplasmic reactivity for PD-L1 is demon-
strable by immunohistochemistry (3,3-diaminobenzidine tetrahy-
drochloride), in this area in all tumour cells (B).
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3The decision to initiate treatment with the PD-1
antibody pembrolizumab as first-line therapy in our
patient was based on the following rationale: first,
treatment is generally well tolerated with less side-effects
compared to other proposed cytotoxic or targeted
therapies. Second, cytotoxic drugs may negatively in-
fluence the immune system, which in turn may cause a
less efficient immune response of PD-1 antibodies in a
second line. Third, because this treatment has a well-
documented high anti-tumoural efficacy in many forms
of solid cancers. As we did not perform any adjuvant
therapy (i.e. radiotherapy) before and during treatment,
the observed signs of regression of the mediastinal
lymph nodes and the stable disease in the lungs can be
regarded as partial response to the applied therapy. To
the best of our knowledge, this is the first report showing
an ongoing partial response of metastatic cutaneous
adenocarcinoma after 1 year of treatment. Notably, for
the use of pembrolizumab in nonesmall cell lung cancer,
the proof of PD-L1 expression by validated immuno-
histochemistry is required and should reveal immuno-
reactivity in more than 50% of tumour cells (equalling a
strong positivity). This was demonstrable in our case.
Interestingly, an intense cytoplasmic immunoreactivity
was found which may be caused by the apocrine dif-
ferentiation of the tumour cells.
In conclusion, although metastatic cutaneous
apocrine carcinoma is rare, it represents a major thera-
peutic challenge. Our case suggests that inhibition of
PD-1 may be considered as first-line therapy for patients
with metastatic disease.
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